Phase one of the expansion, which involves an investment of £4.5m, will provide a non-GMP formulation development facility for the development and scale-up of solid oral dose drug products.
Phase two of the project will comprise expansion of GMP analytical support capabilities with the construction of two additional QC laboratories within the new facility.
Curretly, the GMP development facilities are concerned with drug products up to pilot scale and registration, while the new facility will operate at lab-scale, with batch sizes for most technologies.